Moxifloxacin ameliorates clinical disease activity and histopathological changes of acetic acid-induced colitis model in rat possibly through its effect on proinflammatory mediators and oxidative stress

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Moxifloxacin shows potential to reduce proinflammatory cytokines and oxidative stress in ulcerative colitis model, indicating therapeutic benefits.

Moxifloxacin administration significantly decreased disease activity and histopathological changes induced by acetic acid.
Key metrics include a drop in proinflammatory cytokine IL-1β and myeloperoxidase (MPO) levels following treatment.
The analysis involved a controlled experiment with male Wistar rats across four groups receiving different treatments.
These findings support the potential use of Moxifloxacin for managing ulcerative colitis, suggesting it may be an effective therapeutic option.

Dawood et al. (2023) studied this question.

View Full Paper

Ask AI

Bookmark

Moxifloxacin shows potential to reduce proinflammatory cytokines and oxidative stress in ulcerative colitis model, indicating therapeutic benefits.